Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
67 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Chronic Urticaria Or Hives - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Chronic Urticaria Or Hives - Pipeline Review, H2 2014', provides an overview of the Chronic Urticaria Or Hives's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Urticaria Or Hives, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Urticaria Or Hives and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chronic Urticaria Or Hives and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chronic Urticaria Or Hives products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chronic Urticaria Or Hives pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Urticaria Or Hives - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Chronic Urticaria Or Hives Overview 7 Therapeutics Development 8 Pipeline Products for Chronic Urticaria Or Hives - Overview 8 Pipeline Products for Chronic Urticaria Or Hives - Comparative Analysis 9 Chronic Urticaria Or Hives - Therapeutics under Development by Companies 10 Chronic Urticaria Or Hives - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Chronic Urticaria Or Hives - Products under Development by Companies 13 Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development 14 AstraZeneca PLC 14 Biofrontera AG 15 Bristol-Myers Squibb Company 16 ELORAC, Inc. 17 F. Hoffmann-La Roche Ltd. 18 FAES Farma SA 19 Genentech, Inc. 20 Merck & Co., Inc. 21 Chronic Urticaria Or Hives - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 abatacept (recombinant) - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 AZD-1981 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 BF-Derm-1 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 bilastine - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 cidoxepin hydrochloride - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 desloratadine - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 JDP-205 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 omalizumab - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 quilizumab - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Chronic Urticaria Or Hives - Recent Pipeline Updates 45 Chronic Urticaria Or Hives - Dormant Projects 52 Chronic Urticaria Or Hives - Discontinued Products 53 Chronic Urticaria Or Hives - Product Development Milestones 54 Featured News & Press Releases 54 Aug 28, 2014: Novartis announces that Xolair is approved in Canada as a licensed therapy for chronic idiopathic urticaria (CIU) patients unresponsive to antihistamines 54 May 07, 2014: FDA Approves Xolair for Treatment of Chronic Hives 55 Mar 21, 2014: Novartis announces US FDA approval of Xolair for chronic idiopathic urticaria 55 Mar 06, 2014: Novartis announces Xolair approved in EU as first and only licensed therapy for chronic spontaneous urticaria patients unresponsive to antihistamines 57 Jan 24, 2014: Novartis reports positive opinion from CHMP for Xolair in severe form of skin disease CSU, a debilitating form of hives and chronic itch 58 Oct 11, 2013: FDA Files Genentech's Supplemental Biologics License Application of Xolair for Chronic Idiopathic Urticaria 60 Sep 30, 2013: Novartis to reveal landmark Phase III results of omalizumab at upcoming EADV 2013 congress 61 Jun 26, 2013: Novartis Reports New Phase III Data Showing Omalizumab Significantly Improves Itch In Patients With Severe Form Of CSU 62 Mar 20, 2013: Omalizumab Shows Promise In Eliminating Symptoms Of Chronic Urticaria, Study Finds 64 Feb 24, 2013: Genentech Reports Omalizumab Meets Primary Endpoint In Phase III Results In Patients With Chronic Form Of Hives Who Failed Standard Therapy 64 Appendix 66 Methodology 66 Coverage 66 Secondary Research 66 Primary Research 66 Expert Panel Validation 66 Contact Us 67 Disclaimer 67
List of Tables Number of Products under Development for Chronic Urticaria Or Hives, H2 2014 8 Number of Products under Development for Chronic Urticaria Or Hives - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 10 Comparative Analysis by Late Stage Development, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Chronic Urticaria Or Hives - Pipeline by AstraZeneca PLC, H2 2014 14 Chronic Urticaria Or Hives - Pipeline by Biofrontera AG, H2 2014 15 Chronic Urticaria Or Hives - Pipeline by Bristol-Myers Squibb Company, H2 2014 16 Chronic Urticaria Or Hives - Pipeline by ELORAC, Inc., H2 2014 17 Chronic Urticaria Or Hives - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 18 Chronic Urticaria Or Hives - Pipeline by FAES Farma SA, H2 2014 19 Chronic Urticaria Or Hives - Pipeline by Genentech, Inc., H2 2014 20 Chronic Urticaria Or Hives - Pipeline by Merck & Co., Inc., H2 2014 21 Assessment by Monotherapy Products, H2 2014 22 Number of Products by Stage and Target, H2 2014 24 Number of Products by Stage and Mechanism of Action, H2 2014 26 Number of Products by Stage and Route of Administration, H2 2014 28 Number of Products by Stage and Molecule Type, H2 2014 30 Chronic Urticaria Or Hives Therapeutics - Recent Pipeline Updates, H2 2014 45 Chronic Urticaria Or Hives - Dormant Projects, H2 2014 52 Chronic Urticaria Or Hives - Discontinued Products, H2 2014 53
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.